NCT02863991 2024-07-03
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Jazz Pharmaceuticals
Phase 1/2 Terminated
Clinical Trials
3 trialsNCT02609230 2021-06-04
A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
Fox Chase Cancer Center
Phase 1 Completed
NCT03492138 2020-05-29
Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Icahn School of Medicine at Mount Sinai
Phase 1/2 Terminated